Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
about
Antibody-drug conjugates--an emerging class of cancer treatmentStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsMechanisms of action of therapeutic antibodies for cancerGlycosylation profiles determine extravasation and disease-targeting properties of armed antibodiesComputational selection of antibody-drug conjugate targets for breast cancer.Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell CarcinomaLinker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.Emerging formats for next-generation antibody drug conjugates.Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates.An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.A recombinant fusion protein derived from dog hookworm inhibits autoantibody-induced dermal-epidermal separation ex vivo.Mechanism of action of AminoCBIs: highly reactive but highly cytotoxic analogues of the duocarmycins.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in miceConstruction of homogeneous antibody-drug conjugates using site-selective protein chemistry
P2860
Q26770312-8277620C-E9A3-496D-ABF2-42DF2F47A377Q26780335-97C2307F-6B4E-4E20-AF04-7A70F567DE3BQ28385366-420B3BEB-760E-446F-B5F2-4EE96BEF0E3FQ35129041-0C6C9312-768D-42FA-B432-970CF6FD991EQ36771856-F74BDACC-C973-4922-A59E-E403FCA3390AQ37559487-11779610-F624-4094-88AC-4F4DC4B9B6CDQ37606966-3E45D429-B488-4AE1-9656-8C29AA441DDFQ38386705-6620C28A-9D39-4F2A-ACA5-C589F837A770Q38726647-C8145B24-2260-407A-9479-256F95C11412Q38765188-1E103114-013F-4BC3-9827-57BA58F4F6E9Q38817525-2AD9C526-D4BC-40CF-9B8B-20F9B9947D08Q38842103-A2FD04EC-9437-4590-B922-ADD046ED7F61Q38920359-6B5875AF-A926-4993-B2DC-03F3DD87F34EQ41221244-34AECE65-0ED8-41BA-B72A-08BB83DC287EQ41239615-4FBD9B3D-F4E7-4BD1-BC31-8D5A622ADFBFQ41280225-DD454301-BC8A-41CC-A0A1-744874D65371Q42314398-7C64F3E9-B31A-46A1-97C2-77764DEFC763Q45869295-B31D6E01-FE98-49FE-BAFC-A34FE547A2B0Q46700855-8BEC5465-B3C6-495F-9B52-48274DDA71CCQ46857107-3DDCCA4D-2051-4E8C-BE08-10B6D0B2E9E9Q47143718-BC01FD1D-CB28-4611-AA39-036CA460D84FQ48199774-63CEE7A5-73FC-4AA8-9B51-F5F688C9AFF9Q48226060-3E23628B-DD4D-4827-959B-0AE739D18770Q52565554-739233BC-9566-4327-819B-A26D9B9C0645Q52704026-F916AD84-B4E9-4811-95A7-9B8CF391D913Q55040576-203CAE28-31A6-4C2B-9DEF-CC2ECD9FF73BQ57911942-7403DD59-5008-4224-AFBF-DE405CEBCC44Q57976132-FB770628-8F29-49B3-A6CF-E673F10526A7
P2860
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@en
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@nl
type
label
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@en
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@nl
prefLabel
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@en
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@nl
P2093
P1433
P1476
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
@en
P2093
Elena Perrino
Francesca Pretto
Giulio Casi
Martina Steiner
Nikolaus Krall
P304
P356
10.1158/0008-5472.CAN-13-2990
P407
P577
2014-02-11T00:00:00Z